Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00665145 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509
A Phase 2 study, sponsored by Sangamo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00665145 is a Phase 2 study that has completed, run by Sangamo Therapeutics. The registered enrollment target is 23 participants.
The verdict
NCT00665145, a Phase 2 study, has completed, sponsored by Sangamo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The primary and secondary objectives of this study are: Primary: To evaluate stem-cell-mobilization in subjects with diabetic neuropathy receiving SB-509. Stem cell mobilization will be assessed by evaluating the presence of stem cells circulating in peripheral blood. Secondary: To evaluate the safety of SB-509 in subjects treated with SB-509 with diabetic neuropathy; and to compare the effect of SB-509 versus placebo on a pre-defined multi-endpoint analysis that includes visual analog scale for pain intensity (VASPI), total neuropathy score (TNS), evoked nerve conduction velocity (NCV) and quantitative sensory testing (QST)
Interventions
- DRUG Placebo
- DRUG SB-509
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00665145
The ClinicalTrials.gov registry entry for NCT00665145 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00665145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00665145 about?
NCT00665145 is a clinical study titled "Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509". The primary and secondary objectives of this study are: Primary: To evaluate stem-cell-mobilization in subjects with diabetic neuropathy receiving SB-509. Stem cell mobilization will be assessed by evaluating the presence of stem cells circulating in peripheral blood. Secondary: To evaluate the sa...
What is the current status of trial NCT00665145?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2008-01. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00665145?
The interventions under investigation include: Placebo (DRUG), SB-509 (DRUG).
Who is sponsoring clinical trial NCT00665145?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.